Tempo Therapeutics Inc

Tempo Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, pioneering tissue engineering and regenerative medicine through its proprietary MAP (Microporous Annealed Particle) biomaterial science technology. MAP enables accelerated and improved tissue healing by providing a scaffold that supports natural biological repair processes, with applications spanning complex wound closure, surgical excisions, and broader soft tissue regeneration. The company has conducted its first-in-human clinical trial of MAP biomaterial technology and has received investment from Galaxy-Sirius Partners and Johnson & Johnson Innovation.